Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR | P43119 | 10/20 | 0.46 |
| ▸ | CASR | P41180 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2190445 | 1.00 | PTGIR (0.46) | PTGIRCASRCA2HTR1A | |
| SCHEMBL730472 | 0.83 | PTGIR (0.46) | PTGIRCA2 | |
| SCHEMBL9455313 | 0.83 | GRM2 (0.49) | CASRHTR1A | |
| SCHEMBL14367854 | 0.81 | CASR (0.47) | PTGIRCASRHTR1A | |
| SCHEMBL14367871 | 0.81 | CASR (0.47) | PTGIRCASRHTR1A | |
| SCHEMBL14463199 | 0.81 | PTGIR (0.35) | PTGIR | |
| SCHEMBL1545420 | 0.78 | CA2 (0.55) | CA2 | |
| SCHEMBL7982000 | 0.78 | CA2 (0.55) | CA2 | |
| SCHEMBL2544576 | 0.78 | CA2 (0.55) | CA2 | |
| SCHEMBL31343616 | 0.76 | GRM2 (0.52) | PTGIRCASRCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7348426-B1 | Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents | DR. REDDY'S LABORATIES LIMITED (IN) | 2008-03-25 | — | — | US | disclosed |
| US-6846824-B2 | Bicyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LTD. (IN) | 2005-01-25 | — | — | US | disclosed |
| US-6809095-B2 | NOVEL ANTITOBESITY AND HYPOCHOLESTEROLEMIC COMPOUNDS LOWER TOTAL CHOLESTEROL; INCREASE HIGH DENSITY LIPOPROTEIN (HDL) AND DECREASE LOW DENSTIY LIPOPROTEIN | DR. REDDY'S LABORATORIES LTD. (IN) | 2004-10-26 | — | — | US | disclosed |
| US-20020082258-A1 | Novel bicyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S RESEARCH FOUNDATION & REDDY- CHEMINOR, INC. | 2002-06-27 | — | — | US | disclosed |
| EP-1175412-A1 | SUBSTITUTED BICYCLIC HETEROCYCLES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTIOBESITY AND HYPOCHOLESTEROLEMIC AGENTS | Dr. Reddy's Research Foundation (IN) | 2002-01-30 | — | — | EP | disclosed |
| US-20010051619-A1 | Novel bicyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S RESEARCH FOUNDATION AND REDDY-CHEMINOR, INC. | 2001-12-13 | — | — | US | disclosed |
| US-6265401-B1 | ANTIDIABETIC AGENTS | REDDY-CHEMINOR, INC. | 2001-07-24 | — | — | US | disclosed |
| EP-1082313-A1 | BICYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2001-03-14 | — | — | EP | disclosed |
| WO-2000066572-A1 | SUBSTITUTED BICYCLIC HETEROCYCLES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTIOBESITY AND HYPOCHOLESTEROLEMIC AGENTS | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2000-11-09 | — | — | WO | disclosed |
| WO-1999020614-A1 | BICYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S RESEARCH FOUNDATION (IN) | 1999-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051619-A1 | Novel bicyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them | CPT1A, GPR119, SLC5A1 | PTGIR 665/4885CASR 4037/4885CA2 3517/4885 |
| US-20020082258-A1 | Novel bicyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them | SLC5A1, CYP11B1, CYP4A11 | PTGIR 1359/4885CASR 3791/4885CA2 2467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.